Alnylam Pharmaceuticals (NASDAQ: [[ticker:ALNY]]), the Cambridge, MA-based developer of RNA interference drug technology, said today it has started an early-phase clinical trial of a treatment for liver cancer. The trial is important because it is Alnylam’s first attempt to make an RNAi drug that can circulate throughout the body, as CEO John Maraganore explained in this interview in December. The trial will enroll 55 patients with liver cancer in the U.S.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
